Update on Novo Nordisk manufacturing deviation for NovoSeven©, resulting in shortages for NovoEight© and Esperoct©
Other resources
EHC joins the call for guarantee of meaningful patient involvement and voting rights at the European Medicines Agency
EHC joins EURORDIS–Rare Diseases Europe, the European Patients’ Forum and more than 70 additional patient organisations in calling on EU policymakers to safeguard strong and meaningful patient involvement at the European Medicines Agency (EMA) – including the retention of patient voting rights in the Committee for Medicinal Products for Human Use (CHMP).
European Medicines Agency (EMA) reports a supply shortage of NovoSeven in several EU countries
The supply shortage or limited availability affects some of the EU Member States where the medicine is marketed, including Belgium, Denmark, France, Germany, Luxembourg and Sweden; in some Member States, English-labelled packs for certain doses will be available until the end of 2025.